Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Xilio Therapeutics (XLO) Net Margin (2024 - 2025)

Xilio Therapeutics (XLO) has disclosed Net Margin for 2 consecutive years, with 86.48% as the latest value for Q4 2025.

  • Quarterly Net Margin rose 70406.0% to 86.48% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 95.92% through Dec 2025, up 85903.0% year-over-year, with the annual reading at 95.92% for FY2025, 85903.0% up from the prior year.
  • Net Margin hit 86.48% in Q4 2025 for Xilio Therapeutics, down from 10.12% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 10.12% in Q3 2025 to a low of 790.55% in Q4 2024.